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Successful eradication or control of prevailing infectious diseases is linked to vaccine efficacy, stability and 
distribution. The majority of protein based vaccines are transported at fridge temperatures (‘cold-chain’) to 
maintain their potency. However, this has been shown to be problematic. Proteins are inherently susceptible to 
thermal fluctuations, occurring during transportation, causing them to denature. This leads to ineffective 
vaccines and an increase in vaccine preventable diseases, especially in low-income countries. Our research 
utilizes silica to preserve and eventually distribute vaccines at room temperature, thereby decreasing the load 
on ‘cold-chain’ logistics. The methodology is based upon sol-gel chemistry where soluble silica is employed to 
encapsulate, ensilicate, vaccine proteins1. This yields protein-loaded silica nanoparticles in the form of a dry 
powder (figure 1). The material is stored at room temperature and stress tested (heating, 80°C, 2 hours). 
Subsequently, ensilicated protein is released using a fast chemical process. Silica, silicon dioxide, is an inert 
biocompatible material with certain ceramic properties that is beneficial in this scenario. The proof-of-concept 
work was done with a common vaccine antigen: tetanus toxin C fragment2. This protein is the immunogenic part 
of the full tetanus neurotoxin. Analysis of TTCF protein before and after stabilization in silica revealed full 
retention of protein structure at various levels. Additionally, specific antibody binding indicated retention of 
immunogenic epitopes (figure 2). These finding suggest that this methodology could reduce or perhaps 





Figure 1. FE-SEM TTCF silica 
nanoparticles. 
Figure 2. ELISA TTCF of native vs released1. TTCF protein samples 
coated on a high binding, 96-wells, plate were detected using a 
TTCF specific monoclonal antibody. 
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